Barbara Noiret

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center

No abstract is available for this article. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. DATA AVAILABILITY STATEMENT The data that support the findings of this video are available from the corresponding author upon reasonable request. REFERENCES 1, , , , . Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: A randomized multicenter trial. Ann Surg. 2007; 246(2): 207–214.

Only 1%–4% of all colorectal cancers are located in the anal canal. Histopathologically, two main subtypes are identified: epidermoid (squamous cell) carcinoma, accounting for 85%–90% of cases, and adenocarcinoma arising from the anal glands or cushions, representing 10%–15% [1]. Over recent decades, chemoradiotherapy (CRT) has become the gold standard treatment for epidermoid anal canal carcinoma, owing to advances in chemotherapeutic agents and radiotherapy dosing [1].